Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Dacarbazine. Found 10 abstracts

Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 Sep;29(9):1995-2002.   PMCID: PMC6454486
Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 Sep;146(3):531-7.   PMCID: PMC5783302
LoRusso PM, Infante JR, Kim KB, Burris HA, Curt G, Emeribe U, Clemett D, Tomkinson HK, Cohen RB. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC cancer. 2017 Mar 06;17(1):173.   PMCID: PMC5340007
Czyz M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. 2016 Nov 15;7(46):75551-60.   PMCID: PMC5342760
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15;21(16):3610-8.   PMCID: 4790106
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Gallo JM, Vicini P, Orlansky A, Li S, Zhou F, Ma J, Pulfer S, Bookman MA, Guo P. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. Clinical Cancer Research. 2004 Dec;10(23):8048-58.
Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochemical pharmacology. 2002 Apr;63(7):1219-28.
Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001 Jul 15;61(14):5491-8.
Ma J, Fei ZL, Klein-Szanto A, Gallo JM. Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor. Clin Exp Metastasis. 1998 Aug;16(6):559-68.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Dacarbazine

Dacarbazine Male Alkylating Antineoplastic Agents Female drug therapy Nude Rats pharmacology Aged metabolism Rats Middle Aged analogs & derivatives pathology adverse effects Adult Cultured Tumor Cells Glioblastoma genetics Heterologous Transplantation radiotherapy US Gov't Support-PHS Neoplasm Proteins Sesquiterpenes Young Adult Animal Drug Interactions Xenograft Model Antitumor Assays Combined Modality Therapy Kaplan-Meier Estimate blood me [Metabolism] Brain Neoplasms 80 and over Aged 85622-93-1 (temozolomide) Glioma Trabectedin aa [Analogs & Derivatives] 4342-03-4 (Dacarbazine) drug effects mortality Human administration & dosage Epidermal Growth Factor Receptor Adenosinetriphosphatase Selumetinib Dose-escalation Monoclonal Antibodies Phthalazines blood supply Double-Stranded DNA Breaks 0 (Sesquiterpenes) 73-40-5 (Guanine) Dialysis Solutions Quinazolines ad [Administration & Dosage] Adolescent Phytogenic Antineoplastic Agents Predictive Value of Tests Antineoplastic Agents DNA Ligase ATP Phenotype derivatives Ovarian Neoplasms Microdialysis pd [Pharmacology] Phytogenic) 0 (Antineoplastic Agents immunology de [Drug Effects] 0 (Proto-Oncogene Proteins c-bcl-2) Antineoplastic Combined Chemotherapy Protocols tu [Therapeutic Use] Transfection administration & Kaplan-Meiers Estimate 0 (cyclin-dependent kinase Inhibitor p21) 129298-91-5 (O-(chloroacetylcarbamoyl)fumagillol) Cell Cycle human) EC 3-6-1 (PMS2 protein Melanocytes Carboplatin 0 (Antineoplastic Combined Chemotherapy Protocols) Topotecan analogs & EC 2-1-1-63 (O(6)-Methylguanine-DNA Methyltransferase) O(6)-Methylguanine-DNA Methyltransferase Liposarcoma Alkylating) 0 (Antineoplastic Agents Angiogenesis Inhibitors 0 (Cyclins) Melanoma physiology Multiple Drug Resistance pk Carmustine Radioimmunotherapy Antisense DNA Capillaries Protein p53 Vascular Endothelial Growth Factor A Age Factors 123948-87-8 (Topotecan) Phase 3 Pathologic Neovascularization Drug Synergism 0 (Vascular Endothelial Growth Factor A) Uterine leiomyosarcoma Multivariate Analysis 33069-62-4 (Paclitaxel) 23214-92-8 (Doxorubicin) mammalian) 0 (MLH1 protein Inbred F344 Rats DNA Repair [Pharmacokinetics] Intravenous Administration Cyclins Experimental Neoplasms Piperazines Advanced solid tumors Proportional Hazards Models dosage DNA Repair Enzymes Piperidines Karnofsky Performance Status Animal Disease Models Genetic Vectors deficiency Proto-Oncogene Proteins c-bcl-2 EC 3-6-1-3 (Adenosinetriphosphatase) chemistry Biological Models Synthetic Lethal Mutations pharmacokinetics Doxorubicin melanoma Disease-Free Survival 19916-73-5 (O(6)-benzylguanine) 0 (Protein p53) human) 0 (vascular endothelial growth factor A therapeutic use ph [Physiology] Lymphokines Mice Adjuvant Radiotherapy Antitumor Drug Screening Assays 0 (DNA-Binding Proteins) Leiomyosarcoma bi [Biosynthesis] Tumor Cell Line Docetaxel
Last updated on Wednesday, March 04, 2020